Inactive

Sources Sought Notice for the Japanese Encephalitis Vaccine (JEV) NSN: 6505-01-607-7018 ITEM IDENTIFICATION: Japanese Encephalitis Virus Vaccine, Purified, Inactivated, Single-Dose Prefilled Syringe T... Sources Sought Notice for the Japanese Encephalitis Vaccine (JEV) NSN: 6505-01-607-7018 ITEM IDENTIFICATION: Japanese Encephalitis Virus Vaccine, Purified, Inactivated, Single-Dose Prefilled Syringe The Defense Logistics Agency Troop Support is seeking sources capable of providing the Japanese Encephalitis Vaccine (JEV). DLA Troop Support is contemplating awarding a one-year base indefinite delivery, indefinite quantity contract for the JEV. The contract minimum quantity is 200,060 each. The estimated quantity is 208,320 each and the contract maximum is 300,300 each. However, the quantity may increase or decrease as the Services requirements change. SALIENT CHARACTERISTICS Shall be Japanese Encephalitis Virus Vaccine, Purified, Inactivated. Shall be FDA-approved for active immunization against Japanese Encephalitis disease. Shall be FDA-approved for administration to persons 2 months of age and up. Shall be Vero Cell culture derived. Shall be a sterile suspension. Shall not contain any stabilizers. Shall be Thimerosal/Preservative-free and Latex free. Shall be suitable for intramuscular administration. Shall be supplied as a sterile 0.5 ml suspension in a pre-filled syringe (Type 1 glass) with a plunger stopper (chlorobutyl elastomer) with or without a separate needle. Children 2 months to <3 years of age receive 0.25 mL. Individuals 3 years of age and older receive 0.5 mL. Shall have an expiration dating period of 24 months. Not less than 21 months of the expiration dating period shall remain at time of delivery to the Government. Material shall be shipped under constant refrigeration: 2° - 8° C (35° - 46° F). No excursions permitted. Do Not Freeze. Protect from light. Unit. Each. One each (syringe) containing a single-dose pre-filled syringe, as specified, constitutes one unit. For additional requirements please see the attachment to this announcement titled “JEV MPID 4”. Awardee shall have FDA approval to sell the JEV before award decision. If your firm currently manufactures or distributes the JEV, please provide the information with respect to the following: a) Place of manufacture b) Estimated annual capacity c) FDA registration d) Product name and description including description of any special features e) Current unit sale price f) Estimated inventory level and storage requirements *** NEW PRODUCTS UNDER DEVELOPMENT*** For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture the JEV or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the JEV. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Submit your response to this RFI electronically to Jessica De La Hoz at jessica.delahoz@dla.mil.